Halozyme Therapeutics (HALO) Cash from Investing Activities (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Cash from Investing Activities data on file, last reported at -$2.9 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$2.9 million, up 96.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$458.3 million (down 69.44% YoY), and the FY2025 annual result was -$545.8 million, down 107.75% from the prior year.
• Cash from Investing Activities climbed to -$2.9 million in Q1 2026 per HALO's latest filing, from -$741.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $201.6 million in Q3 2025 and troughed at -$741.8 million in Q4 2025.
• A 5-year average of -$82.1 million and a median of -$42.0 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities tumbled 8178.77% in 2023, then surged 455.57% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$1.7 million in 2022, then plunged by 374.86% to -$8.3 million in 2023, then surged by 455.57% to $29.5 million in 2024, then plunged by 2616.24% to -$741.8 million in 2025, then soared by 99.61% to -$2.9 million in 2026.
• Business Quant data shows HALO's Cash from Investing Activities at -$2.9 million in Q1 2026, -$741.8 million in Q4 2025, and $201.6 million in Q3 2025.